PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1718948
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1718948
Multiple Myeloma Market Assessment, By Drug Class, By Disease Type, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
Global multiple myeloma market is projected to witness a CAGR of 6.01% during the forecast period 2025-2032, growing from USD 26.06 billion in 2024 to USD 41.58 billion in 2032. The multiple myeloma market is being driven by the rising global burden of hematologic cancers, increased adoption of targeted and immunotherapy-based treatments, and strong regional demand across North America. Technological innovations and favorable regulatory approvals are also boosting product launches. Additionally, a shift toward personalized medicine and combination regimens is enhancing patient outcomes and driving further market adoption.
For instance, in February 2025, Opna Bio declared that its oral small molecule inhibitor, OPN-6602, has been granted FDA Orphan Drug designation for the treatment of multiple myeloma. OPN-6602 specifically targets the E1A-binding protein (EP300) and the CREB-binding protein (CBP).
Rising Global Burden of Hematologic Malignancies
The increasing global incidence of multiple myeloma and other hematologic cancers is one of the primary drivers of market growth. Multiple myeloma, a complex and progressive blood cancer, is gaining attention due to aging populations and better diagnostic capabilities. With over 160,000 new cases diagnosed globally in 2023, early diagnosis and awareness initiatives are propelling demand for advanced treatment options. Furthermore, initiatives by cancer organizations and global health bodies are pushing for more accessible and affordable therapies. The expansion of clinical guidelines and real-world data supporting early interventions is also encouraging healthcare providers to adopt newer therapies. Governments and non-profit bodies are investing in nationwide cancer care programs, further creating opportunities for pharmaceutical companies. For instance, the International Myeloma Foundation (IMF) announced its collaboration with SparkCures in October 2024 to offer an innovative service for myeloma patients and their care partners. This service will assist them in identifying clinical trials tailored to their individual results, diagnoses, treatment histories, and personal preferences. By integrating SparkCures' premier clinical trial matching engine and navigation service with the IMF's extensive patient support network, both organizations aim to meet the needs of myeloma patients in finding suitable clinical trials that align with their specific diagnoses or disease conditions.
Continuous Innovations and Targeted Therapy Advancements
Advances in drug development, especially targeted therapies, are revolutionizing the treatment landscape for multiple myeloma. The focus has shifted from broad-spectrum chemotherapy to novel agents such as monoclonal antibodies, bispecific T-cell engagers (BiTEs), and CAR-T cell therapies. These targeted modalities significantly improve progression-free survival and overall response rates, addressing unmet clinical needs. Innovations in proteasome inhibitors and immunomodulators have also enhanced treatment outcomes and reduced toxicity. Pharmaceutical companies are investing heavily in R&D to bring next-generation therapies to market, which promises continued pipeline expansion. Furthermore, regulatory bodies are accelerating the review of novel drug applications under priority review or breakthrough therapy designations, further propelling innovation. In August 2023, the U.S. FDA granted accelerated approval to Talvey (talquetamab-tgvs, Janssen Biotech) for relapsed/refractory multiple myeloma, underscoring the momentum in targeted therapy innovation.
Surge in Anti-CD38 Monoclonal Antibody Usage
Anti-CD38 monoclonal antibodies have emerged as one of the most significant contributors to the growth of the multiple myeloma market. Drugs like daratumumab and isatuximab are being increasingly adopted in both frontline and relapsed settings due to their robust efficacy and tolerability profiles. These therapies are frequently used in combination regimens, enhancing their clinical utility across different disease stages. The rising preference for targeted biologics over traditional chemotherapy also supports the growth of this segment. Integrating anti-CD38 monoclonals into treatment guidelines worldwide has led to higher uptake and better patient outcomes, thereby solidifying their place in standard-of-care regimes. For instance, in July 2024, Sanofi reported a 36.2% year-on-year revenue increase for its anti-CD38 drug Sarclisa, reflecting its strong uptake in global multiple myeloma markets.
North America Maintains Market Leadership
North America, particularly the United States, dominates the global multiple myeloma market due to high healthcare expenditure, advanced treatment availability, and widespread access to innovative drugs. The presence of key players, strong regulatory infrastructure, and robust reimbursement mechanisms also facilitate faster market entry and uptake of new therapies. In addition, strong patient advocacy groups and frequent awareness campaigns lead to early diagnosis and treatment. The region also leads in clinical trials, offering access to cutting-edge therapies under development. Strategic collaborations between pharma companies and research institutions further accelerate innovation and adoption, ensuring that the United States remains the most lucrative market for multiple myeloma therapies. In November 2023, Amgen expanded its oncology R&D center in Massachusetts to accelerate innovation in multiple myeloma and other blood cancers, reaffirming its focus on the United States market. They announced the presentation of new data from their blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego.
Future Market Scenario (2025-2032F)
The global multiple myeloma market is poised for substantial growth over the coming years due to continued advancements in immunotherapy, rising disease prevalence, and increasing healthcare spending. With an expanding elderly population and improved diagnostic capabilities, early detection rates are expected to rise, boosting demand for novel treatments. Furthermore, the growing adoption of combination therapies, personalized medicine, and next-generation biologics such as bispecific antibodies and CAR-T cell therapies will transform the treatment landscape. The market will also benefit from strategic collaborations between pharmaceutical companies and academic institutions aimed at accelerating R&D efforts. North America will likely retain dominance, but emerging markets in Asia-Pacific are anticipated to witness the fastest growth owing to improving healthcare infrastructure and regulatory support.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of multiple myeloma and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For example, in May 2024, Novartis AG declared that it had reached an agreement to acquire Mariana Oncology, a biotechnology firm based in Watertown, Massachusetts, dedicated to the development of radioligand therapies.
Table of Contents
1. Project Scope and Definitions
2. Research Methodology
3. Impact of U.S. Tariffs
4. Executive Summary
5. Global Multiple Myeloma Market Outlook, 2018-2032F
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Class
- 5.2.1.1. Immunomodulators
- 5.2.1.2. Proteasome Inhibitor
- 5.2.1.3. Anti-CD38 Monoclonal Antibody
- 5.2.1.4. Alkylating Agents
- 5.2.1.5. Others
- 5.2.2. By Disease Type
- 5.2.2.1. Active Multiple Myeloma
- 5.2.2.2. Smoldering Multiple Myeloma
- 5.2.3. By Distribution Channel
- 5.2.3.1. Hospital Pharmacies
- 5.2.3.2. Retail Pharmacies and Drug Stores
- 5.2.3.3. Online Pharmacies
- 5.2.4. By Region
- 5.2.4.1. North America
- 5.2.4.2. Europe
- 5.2.4.3. Asia-Pacific
- 5.2.4.4. South America
- 5.2.4.5. Middle East and Africa
- 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
- 5.2.1. By Drug Class
- 5.3. Market Map Analysis, 2024
- 5.3.1. By Drug Class
- 5.3.2. By Disease Type
- 5.3.3. By Distribution Channel
- 5.3.4. By Region
6. North America Multiple Myeloma Market Outlook, 2018-2032F
- 6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
- 6.2. Market Share Analysis & Forecast
- 6.2.1. By Drug Class
- 6.2.1.1. Immunomodulators
- 6.2.1.2. Proteasome Inhibitor
- 6.2.1.3. Anti-CD38 Monoclonal Antibody
- 6.2.1.4. Alkylating Agents
- 6.2.1.5. Others
- 6.2.2. By Disease Type
- 6.2.2.1. Active Multiple Myeloma
- 6.2.2.2. Smoldering Multiple Myeloma
- 6.2.3. By Distribution Channel
- 6.2.3.1. Hospital Pharmacies
- 6.2.3.2. Retail Pharmacies and Drug Stores
- 6.2.3.3. Online Pharmacies
- 6.2.4. By Country Share
- 6.2.4.1. United States
- 6.2.4.2. Canada
- 6.2.4.3. Mexico
- 6.2.1. By Drug Class
- 6.3. Country Market Assessment
- 6.3.1. United States Multiple Myeloma Market Outlook, 2018-2032F*
- 6.3.1.1. Market Size Analysis & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share Analysis & Forecast
- 6.3.1.2.1. By Drug Class
- 6.3.1.2.1.1. Immunomodulators
- 6.3.1.2.1.2. Proteasome Inhibitor
- 6.3.1.2.1.3. Anti-CD38 Monoclonal Antibody
- 6.3.1.2.1.4. Alkylating Agents
- 6.3.1.2.1.5. Others
- 6.3.1.2.2. By Disease Type
- 6.3.1.2.2.1. Active Multiple Myeloma
- 6.3.1.2.2.2. Smoldering Multiple Myeloma
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.2.3.1. Hospital Pharmacies
- 6.3.1.2.3.2. Retail Pharmacies and Drug Stores
- 6.3.1.2.3.3. Online Pharmacies
- 6.3.1.2.1. By Drug Class
- 6.3.1.1. Market Size Analysis & Forecast
- 6.3.2. Canada
- 6.3.3. Mexico
- 6.3.1. United States Multiple Myeloma Market Outlook, 2018-2032F*
All segments will be provided for all regions and countries covered
7. Europe Multiple Myeloma Market Outlook, 2018-2032F
- 7.1. Germany
- 7.2. France
- 7.3. Italy
- 7.4. United Kingdom
- 7.5. Russia
- 7.6. Netherlands
- 7.7. Spain
- 7.8. Turkey
- 7.9. Poland
8. Asia-Pacific Multiple Myeloma Market Outlook, 2018-2032F
- 8.1. India
- 8.2. China
- 8.3. Japan
- 8.4. Australia
- 8.5. Vietnam
- 8.6. South Korea
- 8.7. Indonesia
- 8.8. Philippines
9. South America Multiple Myeloma Market Outlook, 2018-2032F
- 9.1. Brazil
- 9.2. Argentina
10. Middle East and Africa Multiple Myeloma Market Outlook, 2018-2032F
- 10.1. Saudi Arabia
- 10.2. UAE
- 10.3. South Africa
11. Demand Supply Analysis
12. Value Chain Analysis
13. Porter's Five Forces Analysis
14. PESTLE Analysis
15. Pricing Analysis
16. Market Dynamics
- 16.1. Market Drivers
- 16.2. Market Challenges
17. Market Trends and Developments
18. Regulatory Framework and Innovation
- 18.1. Regulatory Approvals
- 18.2. Clinical Trials
19. Patent Landscape
20. Case Studies
21. Competitive Landscape
- 21.1. Competition Matrix of Top 5 Market Leaders
- 21.2. SWOT Analysis for Top 5 Players
- 21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Novartis AG
- 21.3.1.1. Company Details
- 21.3.1.2. Key Management Personnel
- 21.3.1.3. Products and Services
- 21.3.1.4. Financials (As Reported)
- 21.3.1.5. Key Market Focus and Geographical Presence
- 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 21.3.2. Takeda Pharmaceutical Company Limited
- 21.3.3. Amgen, Inc.
- 21.3.4. AbbVie Inc.
- 21.3.5. Teva Pharmaceuticals, Inc.
- 21.3.6. Bristol-Myers Squibb Company
- 21.3.7. Janssen Global Services, LLC
- 21.3.8. Sanofi S.A.
- 21.3.9. Ono Pharmaceutical Co., Ltd.
- 21.3.10. Genentech, Inc.
- 21.3.1. Novartis AG
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
22. Strategic Recommendations
23. About Us and Disclaimer
List of Tables
- Table 1. Competition Matrix of Top 5 Market Leaders
- Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 3. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 2. Global Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 3. Global Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 4. Global Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 5. Global Multiple Myeloma Market Share (%), By Region, 2018-2032F
- Figure 6. North America Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 7. North America Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 8. North America Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 9. North America Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 10. North America Multiple Myeloma Market Share (%), By Country, 2018-2032F
- Figure 11. United States Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 12. United States Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 13. United States Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 14. United States Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 15. Canada Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 16. Canada Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 17. Canada Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 18. Canada Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 19. Mexico Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 20. Mexico Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 21. Mexico Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 22. Mexico Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 23. Europe Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 24. Europe Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 25. Europe Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 26. Europe Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 27. Europe Multiple Myeloma Market Share (%), By Country, 2018-2032F
- Figure 28. Germany Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 29. Germany Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 30. Germany Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 31. Germany Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 32. France Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 33. France Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 34. France Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 35. France Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 36. Italy Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 37. Italy Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 38. Italy Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 39. Italy Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 40. United Kingdom Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 41. United Kingdom Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 42. United Kingdom Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 43. United Kingdom Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 44. Russia Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 45. Russia Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 46. Russia Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 47. Russia Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 48. Netherlands Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 49. Netherlands Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 50. Netherlands Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 51. Netherlands Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 52. Spain Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 53. Spain Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 54. Spain Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 55. Spain Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 56. Turkey Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 57. Turkey Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 58. Turkey Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 59. Turkey Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 60. Poland Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 61. Poland Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 62. Poland Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 63. Poland Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 64. South America Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 65. South America Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 66. South America Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 67. South America Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 68. South America Multiple Myeloma Market Share (%), By Country, 2018-2032F
- Figure 69. Brazil Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 70. Brazil Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 71. Brazil Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 72. Brazil Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 73. Argentina Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 74. Argentina Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 75. Argentina Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 76. Argentina Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 77. Asia-Pacific Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 78. Asia-Pacific Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 79. Asia-Pacific Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 80. Asia-Pacific Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 81. Asia-Pacific Multiple Myeloma Market Share (%), By Country, 2018-2032F
- Figure 82. India Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 83. India Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 84. India Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 85. India Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 86. China Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 87. China Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 88. China Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 89. China Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 90. Japan Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 91. Japan Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 92. Japan Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 93. Japan Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 94. Australia Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 95. Australia Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 96. Australia Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 97. Australia Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 98. Vietnam Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 99. Vietnam Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 100. Vietnam Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 101. Vietnam Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 102. South Korea Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 103. South Korea Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 104. South Korea Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 105. South Korea Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 106. Indonesia Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 107. Indonesia Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 108. Indonesia Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 109. Indonesia Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 110. Philippines Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 111. Philippines Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 112. Philippines Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 113. Philippines Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 114. Middle East & Africa Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 115. Middle East & Africa Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 116. Middle East & Africa Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 117. Middle East & Africa Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 118. Middle East & Africa Multiple Myeloma Market Share (%), By Country, 2018-2032F
- Figure 119. Saudi Arabia Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 120. Saudi Arabia Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 121. Saudi Arabia Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 122. Saudi Arabia Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 123. UAE Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 124. UAE Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 125. UAE Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 126. UAE Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 127. South Africa Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
- Figure 128. South Africa Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
- Figure 129. South Africa Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
- Figure 130. South Africa Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
- Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 132. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
